The most important takeaway from the study is that these data suggest that CD47 is an attractive target for drug development.

Morris and colleagues performed a retrospective analysis of 64 patients with MSI-H/dMMR metastatic colorectal cancer who were treated with an ICI targeting PD-1 or PD-L1, alone (48 patients) or in ...

Patients with dMMR colon cancer in a trial for two neoadjuvant cycles of nivolumab/ipilimumab or nivolumab/relatlimab, had ...

Scientists at Pohang University of Science and Technology (POSTECH) and ShanghaiTech University have achieved a breakthrough ...

Three monoclonal antibodies (cetuximab, bevacizumab and panitumumab) have been approved for the treatment of colorectal cancer in the USA and a large number of other monoclonal antibodies are ...

Agenus Inc. ( (AGEN) ) has released its Q3 earnings. Here is a breakdown of the information Agenus Inc. presented to its investors. Agenus Inc.

What is it and what are the symptoms? - James Van Der Beek shares six children with his wife Kimberly Van Der Beek ...

For rectal cancer, treatment may include options like chemotherapy, radiation, surgery and immunotherapy, according to the ...

Treatment varies depending on how far the cancer has advanced and where in the bowel it is, but it can include surgery, ...

Immunotherapy is a kind of cancer treatment that uses your body's own immune system to find and kill cancer cells. Your immune system is great at fighting infections from outside invaders ...

Encouraging Preclinical Data: Decoy20 has produced efficacy in preclinical studies across a variety of tumor types and in combination with four different classes of existing drugs, demonstrating both ...

Three monoclonal antibodies (cetuximab, bevacizumab and panitumumab) have been approved for the treatment of colorectal cancer in the USA and a large number of other monoclonal antibodies are ...